CO2019014840A2 - Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett - Google Patents
Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rettInfo
- Publication number
- CO2019014840A2 CO2019014840A2 CONC2019/0014840A CO2019014840A CO2019014840A2 CO 2019014840 A2 CO2019014840 A2 CO 2019014840A2 CO 2019014840 A CO2019014840 A CO 2019014840A CO 2019014840 A2 CO2019014840 A2 CO 2019014840A2
- Authority
- CO
- Colombia
- Prior art keywords
- self
- mecp2
- rett syndrome
- regulatory
- aav vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En algunos aspectos, la divulgación se relaciona con composiciones y métodos de ingeniería de un transgén. En algunas modalidades, la divulgación se relaciona con ácidos nucleicos recombinantes autorreguladores, vectores virales y composiciones farmacéuticas que comprenden un transgén de MeCP2. En algunas modalidades, las composiciones y métodos descritos por la divulgación son útiles para tratar enfermedades y desórdenes asociados con una pérdida de mutación de función, por ejemplo, síndrome de Rett.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762516060P | 2017-06-06 | 2017-06-06 | |
PCT/US2018/036200 WO2018226785A1 (en) | 2017-06-06 | 2018-06-06 | Self-regulating aav vectors for safe expression of mecp2 in rett syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019014840A2 true CO2019014840A2 (es) | 2020-01-17 |
Family
ID=64567243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0014840A CO2019014840A2 (es) | 2017-06-06 | 2019-12-27 | Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett |
Country Status (15)
Country | Link |
---|---|
US (2) | US11680275B2 (es) |
EP (1) | EP3635122A4 (es) |
JP (2) | JP2020522269A (es) |
KR (1) | KR20200015701A (es) |
CN (1) | CN111065742A (es) |
AU (1) | AU2018281145A1 (es) |
BR (1) | BR112019025732A2 (es) |
CA (1) | CA3066623A1 (es) |
CL (1) | CL2019003582A1 (es) |
CO (1) | CO2019014840A2 (es) |
EA (1) | EA201992882A1 (es) |
IL (1) | IL271170A (es) |
MX (1) | MX2019014760A (es) |
SG (1) | SG11201911737PA (es) |
WO (1) | WO2018226785A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
MX2019005874A (es) * | 2016-11-17 | 2020-02-07 | Nationwide Childrens Hospital Inc | Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg. |
JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
JP2022530095A (ja) * | 2019-04-24 | 2022-06-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | レット症候群の治療に有用な組成物 |
WO2020234363A2 (en) * | 2019-05-21 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome |
CA3157700A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
EP4069263A4 (en) * | 2019-12-05 | 2024-03-06 | Univ Texas | TRANSGENIC CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE |
US20230151359A1 (en) * | 2020-03-09 | 2023-05-18 | University Of Massachusetts | Gene replacement therapy for foxg1 syndrome |
WO2021230987A1 (en) * | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
IL300728A (en) * | 2020-08-19 | 2023-04-01 | Sarepta Therapeutics Inc | Adeno-associated virus vectors for the treatment of Rett syndrome |
CN113754727B (zh) * | 2020-09-30 | 2022-07-12 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
WO2022094078A1 (en) * | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
GB202201242D0 (en) * | 2022-01-31 | 2022-03-16 | Univ Edinburgh | Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
US20040106566A1 (en) | 2002-05-17 | 2004-06-03 | Shi-Lung Lin | RNA-splicing and processing-directed gene silencing and the relative applications thereof |
JP2011501760A (ja) | 2007-10-23 | 2011-01-13 | ノバルティス アーゲー | 呼吸器疾患の処置のためのtrkb抗体の使用 |
BRPI0906877A2 (pt) | 2008-01-17 | 2015-07-28 | Irm Llc | Anticorpos anti-trkb aperfeiçoados |
WO2010105096A2 (en) | 2009-03-11 | 2010-09-16 | University Of Massachusetts | Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212) |
EA201390616A1 (ru) | 2010-10-25 | 2013-09-30 | Юниверсите Д'Экс-Марсель | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 |
US20160000794A1 (en) * | 2012-09-25 | 2016-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods for the diagnosis and treatment of sjogren's syndrome |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
US10072251B2 (en) | 2014-02-19 | 2018-09-11 | University Of Massachusetts | Recombinant AAVS having useful transcytosis properties |
US10975391B2 (en) * | 2014-04-25 | 2021-04-13 | University Of Massachusetts | Recombinant AAV vectors useful for reducing immunity against transgene products |
WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
JP6842410B2 (ja) | 2014-10-03 | 2021-03-17 | ユニバーシティ オブ マサチューセッツ | 新規の高効率ライブラリーにより同定されるaavベクター |
CN107073051B (zh) | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
EP3121284A1 (en) * | 2015-07-22 | 2017-01-25 | Ecole Polytechnique Federale de Lausanne (EPFL) | Bicistronic aav vector for rna interference in als |
-
2018
- 2018-06-06 MX MX2019014760A patent/MX2019014760A/es unknown
- 2018-06-06 CA CA3066623A patent/CA3066623A1/en active Pending
- 2018-06-06 BR BR112019025732-2A patent/BR112019025732A2/pt unknown
- 2018-06-06 AU AU2018281145A patent/AU2018281145A1/en active Pending
- 2018-06-06 SG SG11201911737PA patent/SG11201911737PA/en unknown
- 2018-06-06 JP JP2019567677A patent/JP2020522269A/ja active Pending
- 2018-06-06 US US16/619,733 patent/US11680275B2/en active Active
- 2018-06-06 EA EA201992882A patent/EA201992882A1/ru unknown
- 2018-06-06 CN CN201880051148.4A patent/CN111065742A/zh active Pending
- 2018-06-06 EP EP18812887.0A patent/EP3635122A4/en active Pending
- 2018-06-06 KR KR1020207000120A patent/KR20200015701A/ko not_active Application Discontinuation
- 2018-06-06 WO PCT/US2018/036200 patent/WO2018226785A1/en unknown
-
2019
- 2019-12-04 IL IL271170A patent/IL271170A/en unknown
- 2019-12-06 CL CL2019003582A patent/CL2019003582A1/es unknown
- 2019-12-27 CO CONC2019/0014840A patent/CO2019014840A2/es unknown
-
2023
- 2023-05-03 US US18/311,367 patent/US20230416779A1/en active Pending
- 2023-08-23 JP JP2023135189A patent/JP2023164447A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3066623A1 (en) | 2019-12-13 |
US20200181646A1 (en) | 2020-06-11 |
JP2020522269A (ja) | 2020-07-30 |
US11680275B2 (en) | 2023-06-20 |
BR112019025732A2 (pt) | 2020-06-30 |
SG11201911737PA (en) | 2020-01-30 |
EA201992882A1 (ru) | 2020-05-25 |
JP2023164447A (ja) | 2023-11-10 |
MX2019014760A (es) | 2020-08-03 |
EP3635122A4 (en) | 2021-03-31 |
CN111065742A (zh) | 2020-04-24 |
KR20200015701A (ko) | 2020-02-12 |
AU2018281145A1 (en) | 2020-01-02 |
IL271170A (en) | 2020-01-30 |
CL2019003582A1 (es) | 2020-09-25 |
US20230416779A1 (en) | 2023-12-28 |
EP3635122A1 (en) | 2020-04-15 |
WO2018226785A1 (en) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019014840A2 (es) | Vectores aav auto reguladores para la expresion segura de mecp2 en sidrome de rett | |
BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
ECSP18083561A (es) | Proteínas de fusión gdf15 y usos de estas | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
CO2018005306A2 (es) | Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia | |
CL2020002755A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
CL2016000502A1 (es) | Vectores mejorados del factor viii del virus adeno-asociado de menos de 5,0 kb de longitud, que producen un polipéptido del factor viii funcionalmente activo para el tratamiento de la hemofilia a. | |
UY36611A (es) | Producción de vectores adeno-asociados de gran tamaño | |
CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
AR110632A1 (es) | Vectores del adenovirus canino | |
PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
EA201891138A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
ECSP22049014A (es) | Variantes de progranulina | |
CO2020013557A2 (es) | Variantes de lfa3 y composiciones y usos de las mismas | |
AR104252A1 (es) | Promotor de plantas para expresión transgénica | |
AR121381A2 (es) | Composición farmacéutica que comprende moduladores de actividad complementaria y dispositivo autoinyector | |
AR123756A1 (es) | Construcciones de ácidos nucléicos, vectores virales y partículas virales | |
AR104256A1 (es) | Polipéptido que comprende un epitope de la proteína e del virus del dengue, polinucleótido y constructo genético que lo codifican, partículas similares a virus (vlps) que comprenden dicho polipéptido, célula transgénica que las expresa, vacunas y método para tratar el dengue | |
MY185846A (en) | Oncolytic adenovirus encoding a b7 protein |